Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study

Jianhui Chen; Wen Ye; Wei Jiang; Xiaofan Li; Rong Liu; Bijuan Lin; Jingnan Xiang; Wei Tian; Junjie Bai; Teng Zuo; Bingxin Lin; Yinan Guo; Song Zheng

doi:10.21037/tau-21-111

Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study

Transl Androl Urol. 2021 Mar;10(3):1321-1331. doi: 10.21037/tau-21-111.

Authors

Jianhui Chen¹, Wen Ye¹, Wei Jiang¹, Xiaofan Li^{2

3}, Rong Liu¹, Bijuan Lin⁴, Jingnan Xiang⁵, Wei Tian⁶, Junjie Bai¹, Teng Zuo¹, Bingxin Lin¹, Yinan Guo¹, Song Zheng¹

Affiliations

¹ Department of Urology, Fujian Medical University Union Hospital, Fuzhou, China.
² Department of Hematology, Fujian Institute of Hematology, Union Hospital, Fujian Medical University, Fuzhou, China.
³ Fujian Provincial Key Laboratory on Hematology, Fujian Medical University, Fuzhou, China.
⁴ Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China.
⁵ Department of Emergency, Union Hospital, Fujian Medical University, Fuzhou, China.
⁶ Department of Dermatology, Fujian Medical University Union Hospital, Fuzhou, China.

Abstract

Background: The efficacy and safety of pazopanib in patients diagnosed with metastatic renal cell carcinoma (mRCC) have been demonstrated by a Chinese subgroup analysis of the COMPARZ (Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma) trial. However, the real-world data are still unknown. This single-center, retrospective study was designed to verify the real-world effects of pazopanib in Chinese patients with mRCC.

Methods: Patients with mRCC and a clinical decision to initiate pazopanib as first-line therapy were eligible. The primary endpoint was progression-free survival (PFS), with overall survival (OS), objective response rate (ORR), and safety being evaluated as secondary endpoints. The effectiveness according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk model, number of risk factors in the intermediate risk group, age, Eastern Cooperative Oncology Group (ECOG) performance status (PS), and the number and site of organ metastasis were also assessed.

Results: A total of 32 patients were enrolled, including 23 (71.9%) males and 9 (28.1%) females. The median age was 57 years (range 29-75 years). With a median follow-up time of 23.8 months, a median PFS of 18.3 months, and an ORR of 37.5%. Median OS was not reached, and the 1-, 2-, and 3-year overall survival rates were 90.6%, 78.1, and 65.6%, respectively. According to IMDC risk model, 37.5% were placed in the favorable risk (FR) subgroup, 56.2% (the majority) were placed in the intermediate risk (IR) subgroup, and 6.3% were placed in the poor risk (PR) subgroup. Compared with the IR and PR groups, the FR group achieved the best ORR (58.3%) and median PFS (22.1 months). Having 1 risk factor, ECOG PS <2, 1 organ metastasis site, and only lung metastasis associated with a higher ORR and better median PFS. The IMDC risk model and number of metastases were associated with PFS. The most common adverse events were change in hair color (69.0%), diarrhea (63%), and hypertension (50%).

Conclusions: Pazopanib showed efficacy and safety in real-world Chinese mRCC patients.

Keywords: Metastatic renal cell carcinoma (mRCC); pazopanib; real-world; the International Metastatic Renal Cell Carcinoma Database Consortium risk model (IMDC risk model).